KPL-301 for Subjects With Giant Cell Arteritis
Study sponsor: Kiniksa Pharmaceuticals, Ltd.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-08-13Actual
Enrollment · participants70Actual
Source updated2023-10-23Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.